Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 631 to 640 of 2418

TitleReference numberPublishedLast updated
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Dupilumab for treating moderate to severe atopic dermatitisTA534
Dupilumab for treating moderate to severe prurigo nodularisTA955
Dupilumab for treating severe asthma with type 2 inflammationTA751
DuraGraft for preserving vascular graftsMIB184
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)TA811

Results per page

  1. 10
  2. 25
  3. 50
  4. All